+

WO2007025767A3 - Nanopartikulärer einschluss- und ladungskomplex für pharmazeutische formulierungen - Google Patents

Nanopartikulärer einschluss- und ladungskomplex für pharmazeutische formulierungen Download PDF

Info

Publication number
WO2007025767A3
WO2007025767A3 PCT/EP2006/008567 EP2006008567W WO2007025767A3 WO 2007025767 A3 WO2007025767 A3 WO 2007025767A3 EP 2006008567 W EP2006008567 W EP 2006008567W WO 2007025767 A3 WO2007025767 A3 WO 2007025767A3
Authority
WO
WIPO (PCT)
Prior art keywords
complex
inclusion
relates
pharmaceutical formulations
charge complex
Prior art date
Application number
PCT/EP2006/008567
Other languages
English (en)
French (fr)
Other versions
WO2007025767A2 (de
Inventor
Katrin Claudia Fischer
Sascha General
Georg Roessling
Original Assignee
Schering Ag
Katrin Claudia Fischer
Sascha General
Georg Roessling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Katrin Claudia Fischer, Sascha General, Georg Roessling filed Critical Schering Ag
Publication of WO2007025767A2 publication Critical patent/WO2007025767A2/de
Publication of WO2007025767A3 publication Critical patent/WO2007025767A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft einen nanopartikulären Einschluss- und Ladungskomplex, der mindestens zwei Komplexpartner umfasst, wobei ein Komplexpartner ein anionischer Einschlussbildner und ein anderer Komplexpartner ein kationischer Wirkstoff ist. Genauer betrifft die Erfindung einen Komplex aus anionischem beta-Cyclodextrin-Phosphat und einem (schwach) basischen (niedermolekularen) Wirkstoff im protonierten Zustand. Die Erfindung betrifft weiterhin einen Nanopartikel, der den Einschluss- und Ladungskomplex umfasst. Die Erfindung betrifft auch ein Verfahren zur Herstellung und eine Verwendung des Nanopartikels.
PCT/EP2006/008567 2005-09-02 2006-09-01 Nanopartikulärer einschluss- und ladungskomplex für pharmazeutische formulierungen WO2007025767A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71333205P 2005-09-02 2005-09-02
DE102005041860.0 2005-09-02
DE102005041860A DE102005041860A1 (de) 2005-09-02 2005-09-02 Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US60/713,332 2005-09-02

Publications (2)

Publication Number Publication Date
WO2007025767A2 WO2007025767A2 (de) 2007-03-08
WO2007025767A3 true WO2007025767A3 (de) 2008-09-25

Family

ID=37735477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008567 WO2007025767A2 (de) 2005-09-02 2006-09-01 Nanopartikulärer einschluss- und ladungskomplex für pharmazeutische formulierungen

Country Status (3)

Country Link
US (1) US20070149479A1 (de)
DE (1) DE102005041860A1 (de)
WO (1) WO2007025767A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
DK1778251T3 (da) 2004-07-27 2011-07-18 Gilead Sciences Inc Nukleosidphosphatkonjugater som anti-HIV-midler
ATE534377T1 (de) * 2006-05-16 2011-12-15 Gilead Sciences Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
KR100718280B1 (ko) * 2006-06-08 2007-05-16 재단법인서울대학교산학협력재단 사이클로덱스트린 유도체 입자를 도입한 가소제 유출저감형 폴리염화비닐 성형체 및 그 제조방법
EP2146693A2 (de) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin-zusammensetzungen
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
DE102007059752A1 (de) * 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (de) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanopartikel mit modifizierter Oberfläche
UA103329C2 (ru) 2008-07-08 2013-10-10 Гилиад Сайенсиз, Инк. Соли соединений-ингибиторов вич
US8383632B2 (en) 2008-09-05 2013-02-26 Mcneil-Ppc, Inc. Method for making cetirizine tablets
WO2010124004A2 (en) 2009-04-22 2010-10-28 Emory University Nanocarrier therapy for treating invasive tumors
DK2442650T3 (en) 2009-06-12 2015-12-07 Cynapsus Therapeutics Inc sublingual apomorphine
CA2765635C (en) 2009-06-25 2016-09-06 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
PL2651357T3 (pl) 2010-12-16 2020-08-24 Sunovion Pharmaceuticals Inc. Filmy podjęzykowe
CN102600132B (zh) * 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
CN109288816B (zh) 2018-12-04 2019-11-22 广州凯普医药科技有限公司 一种氯喹凝胶及其制备方法和应用
CN109674744B (zh) * 2019-01-21 2021-09-17 成都欣捷高新技术开发股份有限公司 稳定的盐酸替罗非班液体组合物及其制备方法
US20220265659A1 (en) 2019-09-02 2022-08-25 Inserm (Institut National De La Santé Et De Al Recherche Médicale) Methods and compositions for treating pax6-deficiency related disease
EP4247340A4 (de) * 2020-11-18 2024-10-02 Bexson Biomedical, Inc. Komplexbildnersalzformulierungen von pharmazeutischen verbindungen
WO2022109050A1 (en) * 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
IT202100009857A1 (it) * 2021-04-19 2022-10-19 Univ Degli Studi Di Torino Formulazione a rilascio controllato e prolungato di apomorfina
WO2023225113A1 (en) * 2022-05-18 2023-11-23 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399903A1 (de) * 1989-05-24 1990-11-28 Rhone-Poulenc Sante Imipramin enthaltende Arzneizubereitungen
WO1994016733A1 (en) * 1993-01-29 1994-08-04 Chiesi Farmaceutici S.P.A. Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP2000191704A (ja) * 1998-12-25 2000-07-11 Yokohama Kokusai Bio Kenkyusho:Kk ポリリン酸化サイクロデキストリン、その製造法及び用途
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
WO2005065435A2 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126146C2 (de) * 1990-10-16 1993-09-30 Steag Ag Adsorptionsmittel-, insbesondere Wanderbettreaktor
FI101156B (fi) * 1996-08-30 1998-04-30 Fortum Oil Oy Kiertomassareaktoriin perustuva menetelmä ja laite hiilivetyjen konver toimiseksi
US6240154B1 (en) * 1999-04-06 2001-05-29 Ce Nuclear Power Llc Self-actuated louvers for venting a CEDM cooling system of a nuclear reactor and method of using the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399903A1 (de) * 1989-05-24 1990-11-28 Rhone-Poulenc Sante Imipramin enthaltende Arzneizubereitungen
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1994016733A1 (en) * 1993-01-29 1994-08-04 Chiesi Farmaceutici S.P.A. Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
JP2000191704A (ja) * 1998-12-25 2000-07-11 Yokohama Kokusai Bio Kenkyusho:Kk ポリリン酸化サイクロデキストリン、その製造法及び用途
WO2005065435A2 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200053, Derwent World Patents Index; Class B04, AN 2000-567793, XP002484903, "New polyphosphated cyclodextrins, useful as solubilizing agents for drugs" *
DOLLO G ET AL: "Complexation between local anaesthetics and [beta]-cyclodextrin derivatives relationship between stability constants and in vitro membrane permeability of bupivacaine and lidocaine from their complexes", SCIENCES TECHNIQUES ET PRATIQUES STP PHARMA SCIENCES, PARIS, FR, vol. 8, no. 3, 1 January 1998 (1998-01-01), pages 189 - 195, XP008092958, ISSN: 1157-1489 *
FRANCO M ET AL: "Effect of some hydrophilic cyclodextrins on the solubility, dissolution rate and in vitro percutaneous penetration of oxazepam", JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY 200401 FR, vol. 14, no. 1, January 2004 (2004-01-01), pages 63 - 68, XP008092956, ISSN: 1157-1489 *
HINCAL A A: "Recent advances in drug delivery using amphiphilic cyclodextrin nanoparticles", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 25, no. Suppl. 1, 1 January 2005 (2005-01-01), pages S3 - S4, XP008092932, ISSN: 0928-0987 *
OKIMOTO K ET AL: "DESIGN AND EVALUATION OF AN OSMOTIC PUMP TABLET (OPT) FOR CHLORPROMAZINE USING (SBE)7M-BETA-CD", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 16, no. 4, 1 January 1999 (1999-01-01), pages 549 - 554, XP001105545, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
DE102005041860A1 (de) 2007-03-08
WO2007025767A2 (de) 2007-03-08
US20070149479A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
WO2007025767A3 (de) Nanopartikulärer einschluss- und ladungskomplex für pharmazeutische formulierungen
WO2009120247A3 (en) Lipid nanoparticle compositions and methods of making and using the same
WO2008073171A3 (en) Monodisperse single-walled carbon nanotube populations and related methods for providing same
WO2006128937A3 (es) Nanoparticulas que comprenden quitosano y ciclodextrina
WO2007118653A3 (de) Nanopartikel, enthaltend nicotin und/oder cotinin, dispersionen und die verwendung derselben
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2008082613A3 (en) Factor ix moiety-polymer conjugates having a releasable linkage
WO2007103294A3 (en) Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
WO2007050656A3 (en) Dietary fiber formulation and method of administration
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
WO2006083225A8 (en) Snap-type locking device
WO2007127668A3 (en) Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
AU2003230120A1 (en) Metal delivery system for nanoparticle manufacture
WO2007103356A3 (en) Medical devices having electrically aligned elongated particles
WO2007010034A3 (de) Ampholytisches copolymer, dessen herstellung und verwendung
WO2008008797A3 (en) Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
WO2006105172A3 (en) Peg-polyacetal and peg-polyacetal-poe graft copolymers and pharmaceutical compositions
IL196426A0 (en) Microparticulates based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2006103657A3 (en) A solid composition for intra-oral delivery of insulin
WO2009098404A3 (fr) Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation
WO2007067433A3 (en) Poly(trimethylene terephthalate)/poly(alpha-hydroxy acid) films
WO2007112279A3 (en) Resonators
WO2007067435A3 (en) Poly(trimethylene terephthalate)/poly(alpha-hydroxy acid) bi-constituent filaments
WO2007076233A3 (en) Nanoparticle coating process for fuel cell components

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 06791790

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载